Earlier in the month, Pulmonary Hypertension News Contributing Editor Charles Moore reported on how, according to Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey, those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of the disease. Now, a…
News
Researchers from the University of California, San Diego, presented a new study at the 2014 American Thoracic Society International Conference revealing the effects of pulmonary thromboendarterectomy (PTE) in patients with chronic pulmonary thromboembolic disease, suggesting a positive effect in patients’ conditions after the procedure. Daniel Crouch, MD, pulmonary and critical fellow…
Having less access to health care, pulmonary hypertension patients from lower socioeconomic status present a more advanced state of the disease at the time of initial evaluation, compared to higher socioeconomic groups. These are the results of a study conducted by Long Island Jewish School of Medicine researcher Jose…
Approximately 5,000 Americans are diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) each year. The condition is a result of persistent obstruction of pulmonary blood vessels due to unresolved blood clots from previous episodes of acute pulmonary embolism. If patients do not receive treatment for CTEPH, they may develop…
Last Tuesday, May 13, 2014, the U.S. Food and Drug Administration, together with the Pulmonary Hypertension Association, held a one-of-a-kind forum composed of FDA drug reviewers and patients diagnosed with pulmonary arterial hypertension (PAH). PAH is a condition wherein the lungs’ vasculature constricts and raises blood pressure, eventually…
Clinicians are constantly in need of biomarkers that can be used to non-invasively predict disease status of patients. In the case of pulmonary hypertension, one promising predictor is the N-terminal fragment of the pro-hormone for brain natriuretic peptide: N-terminal pro-brain natriuretic peptide (NT-proBNP). Levels of NT-proBNP are elevated after…
Pulmonary hypertension can result from a number of causes: liver diseases, lung diseases, rheumatic disorders, low oxygen, poor health behaviors and can also be inherited. More than 80% of cases resulting from a genetic predisposition to the disease are due to a mutation in the bone morphogenic protein receptor 2…
According to recent data, there is a direct correlation between pulmonary emboli that result in the onset of pulmonary hypertension (PH) — an under recognized condition that researchers and medical practitioners alike hope to address in the PH patient population. Pulmonary embolism is the clinical condition marked by a…
A small pilot study by a team of French researchers has established the long-term benefits of upfront triple combination therapy among patients with severe pulmonary arterial hypertension (PAH) The U.S. National Library of Medicine (NLM) describes pulmonary arterial hypertension as abnormally high blood pressure in the arteries of the lungs that makes…
Results released Monday, May 5th from Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey revealed that those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of being diagnosed with disease. Chief among the difficulties experienced among the PH…
Bayer HealthCare, a subsidiary of German-owned corporation, Bayer AG, has just announced that it has registered its therapeutic drug Riociguat for regulatory clearance in Japan. The drug has gone through intensive clinical research and development under Bayer, and is eyeing becoming the next novel treatment of two types of…
Bayer Healthcare recently announced the approval of its novel drug Adempas (riociguat), which has been listed by the Régie de l’assurance malady du Québec (RAMQ), the Québec public formulary, as the one and only treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Québec is the first province to provide Adempas…
